October 15, 2024
EVerMed Inc. received investment from SPI as the 2nd closing of its seed round. With this capital increase, EVerMed will accelerate the development of its pipeline.
SPI is a provider of high-quality integrated products and services to the pharmaceutical industry, from research equipment and bioresources for drug discovery, pharmaceutical licensing and research alliance support, to manufacturing of APIs, intermediates for pharmaceuticals, generic drugs and biologics. In the field of EV therapeutics, SPI has involved EV therapeutics supporting businesses by offering EV-producing cell processing services, GMP/GLP compatible safety and viral clearance testing services, and EV contract manufacturing services. SPI has already established a business partnership with EVerMed, but this investment will further strengthen this relationship.